Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients

American Journal of Transplantation

Volumn 2, Issue 2, 2002, Pages 179-185

  Anjuma, Shakeel ^a   Andany, Magdalena Adeva ^b   McCleana, Jeffrey C ^a   Danielson, Barbara ^a   Kasiske, Bertram L ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Acute rejection; Allograft failure; Immunosuppression

Indexed keywords

ALG; AZATHIOPRINE; CYCLOSPORIN A; HLA B ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT REJECTION; HLA MATCHING; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; NEUTROPENIA; OBESITY; RACE DIFFERENCE; RECIPIENT; RISK FACTOR; TREATMENT PLANNING;

ANTILYMPHOCYTE SERUM; CONFIDENCE INTERVALS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; METHYLPREDNISOLONE; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 0346144490     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.020210.x     Document Type: Article

References (29)

1. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-17.
2. Heim-Duthoy KL, Chitwood KK, Tortorice KL, Massy ZA, Kasiske BL. Elective cyclosporine withdrawal one year after renal transplantation. Am J Kidney Dis 1994; 24: 846-853.
3. Kasiske BL, Johnson HJ, Goerdt PJ et al. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 1997; 30: 639-645.
4. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 1986; 314: 1219-1225.
5. Calne RY. Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet 1987; 2: 506-507.
6. Ponticelli C, Minetti L, Quarto Di Palo F et al. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation 1988; 8: 908-913.
7. Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. Arch Intern Med 1990; 150: 280-283.
8. Haas M, Mayer G. Cyclosporin A-associated hypertension - pathomechanisms and clinical consequences. Nephrol Dial Transplant 1997; 12: 395-398
9. Ligtenberg G, Hené RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporine A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-373.
10. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994; 58: 663-669.
11. van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in 't Veld AJ, Jansen H, Weimar W. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients, Kidney Int 1997; 51: 1608-1612.
12. Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA. The effects of cyclosporine and prednisone on serum lipid and (apo)-lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5: 2073-2081.
13. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34: 1-13.
14. Irish AB, Green FR. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1997; 12: 167-173.
15. van den Dorpel MA, Man in 't Veld AJ, Levi M, ten Cate JW, Wouter J, Weimar W. Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. Arterioscler Thromb Vasc Biol 1999; 19: 1555-1558.
16. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
17. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100.
18. Benigni A, Bruzzi I, Mister M et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55: 674-685.
19. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allogratt nephropathy. Kidney Int 2001; 59: 1567-1573.
20. Basadonna GP, Matas AJ, Gillingham KJ et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993-995.
21. Leggat JE, Ojo AO, Leichtman AB et al. Long-term renal allograft survival. Prognostic implication of the timing of acute rejection episodes. Transplantation 1997; 63: 1268-1272.
22. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518-524.
23. Taylor RJ, Andrews W, Rosenthal JT, Carpenter B, Hakala TR. Influence of DR matching in cadaveric renal transplants performed with cyclosporine. A retrospective analysis of one centre. Transplantation 1984; 38: 616-618.
24. Juarez F, Barrios L, Cano L et al. Cyclosporine: has it made a difference between using HLA or not? A comparative study between patients with and without HLA matching. Transplant Proc 1998; 30: 1744-1745.
25. Öst L. Effects of cyclosporine on prednisolone metabolism. Lancet 1984; 1: 451.
26. Langhoff E, Madsen S, Flachs H, Olgaard K, Ladefoged J, Hvidberg EF. Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients. Transplantation 1985; 39: 107-109.
27. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, IJzermans JN, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143-148.
28. Jha V, Muthukumar T, Kohli HS, Sud K, Gupta KL, Sakhuja V. Impact of cyclosporine withdrawal on living-related renal transplants: a single center experience. Am J Kidney Dis 2001; 37: 119-124.
29. Sanders CE, Curtis JJ, Julian BA et al. Tapering or discontinuing cyclosporine for financial reasons - a single-center experience. Am J Kidney Dis 1993; 21: 9-15.